Zobrazeno 1 - 10
of 396
pro vyhledávání: '"K. K. Ray"'
Publikováno v:
Fracture and Structural Integrity, Vol 3, Iss 7, Pp 57-64 (2009)
In this investigation the extent of the plastic zone size ahead of a crack-tip in single edge notched tension (SENT), compact tension (CT) specimens has been examined experimentally by micro-hardness technique and by elastic-plastic finite element an
Externí odkaz:
https://doaj.org/article/d86c835af5e443f1b694a2005e65d93c
Publikováno v:
Fracture and Structural Integrity, Vol 3, Iss 7 (2013)
In this investigation the extent of the plastic zone size ahead of a crack-tip in single edge notched tension (SENT), compact tension (CT) specimens has been examined experimentally by micro-hardness technique and by elastic-plastic finite element an
Externí odkaz:
https://doaj.org/article/138b2e51e8e44b479d2bd43b38d1e8b7
Publikováno v:
European Heart Journal. 43
Background Strategies for the prevention of atherosclerotic cardiovascular disease (ASCVD) are related to individual risk factors, and according to guidelines the higher the risk, the more intense the treatment required. Identifying patients at highe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b74c58e0989db302bb3dfda8fa5545f0
https://doi.org/10.1093/eurheartj/ehac544.2255
https://doi.org/10.1093/eurheartj/ehac544.2255
Publikováno v:
European Heart Journal. 43
Background Lipid-lowering treatments (LLTs) require both adherence and persistence to the treatment regimen long-term to maximise treatment benefits. Small molecules require self-medication daily but therapies such as evolocumab are labelled for self
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::666b88ac05e330192049b8f9a56c5d46
https://doi.org/10.1093/eurheartj/ehac544.2666
https://doi.org/10.1093/eurheartj/ehac544.2666
Publikováno v:
European Heart Journal. 43
Background Variability in LDL-C control at a population level associates with worse CV outcomes. This could in part be related to variations in patient adherence to self-administration regimens or variability in the response to a given therapy. Poten
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::042cef34d71a83fffc9337d325dbb984
https://doi.org/10.1093/eurheartj/ehac544.2667
https://doi.org/10.1093/eurheartj/ehac544.2667
Publikováno v:
European Heart Journal. 43
Background Lowering LDL-C treatment goals in the 2019 ESC/EAS guidelines necessitates greater use of combination therapies (1). Cost of PCSK9 inhibitors (PCSK9i) and efficacy of ezetimibe alone as add on therapies limit population level achievement o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6ffd1bc669b26eb94d11162ce441d07a
https://doi.org/10.1093/eurheartj/ehac544.2377
https://doi.org/10.1093/eurheartj/ehac544.2377
Publikováno v:
European Heart Journal. 43
Background In the 2019 ESC/EAS guidelines, documented ASCVD is a criterion for patients being categorised as at very high cardiovascular (CV) risk, and stringent low-density lipoprotein cholesterol (LDL-C) reductions of ≥50% plus a goal of Purpose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cc3fe421eda920638dc52dfc717bea3f
https://doi.org/10.1093/eurheartj/ehac544.2373
https://doi.org/10.1093/eurheartj/ehac544.2373
Autor:
K K Ray-Ogbonna, H I Wiche
Publikováno v:
British Journal of Library and Information Management. 1:1-15
The study investigated information needs and seeking behaviour of medical students of PAMO University of medical sciences Port Harcourt, Rivers State. Five objectives and five research questions guided the study. The researcher adopted a descriptive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca54d406908287d9532c4056cf4ad30b
https://doi.org/10.52589/bjlim-qd2yvzoy
https://doi.org/10.52589/bjlim-qd2yvzoy
Autor:
W Koenig, K K Ray, D G Kallend, U Landmesser, L A Leiter, G G Schwartz, R S Wright, L Garcia Conde, M Jaros, F J Raal
Publikováno v:
European Heart Journal. 42
Background Approximately 25% of patients (pts) with atherosclerotic cardiovascular disease (ASCVD) have polyvascular disease (PVD), which involves ≥2 coronary, cerebrovascular, and peripheral artery beds. PVD is an independent predictor of major ad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6445cd969a26f77feba71bf10728a7cf
https://doi.org/10.1093/eurheartj/ehab724.2025
https://doi.org/10.1093/eurheartj/ehab724.2025
Autor:
W Koenig, K K Ray, D G Kallend, U Landmesser, L A Leiter, G G Schwartz, R S Wright, L Garcia Conde, M Jaros, F J Raal
Publikováno v:
European Heart Journal. 42
Background Patients (pts) with hyperlipidaemia and established cerebrovascular disease (CeVD) are at an increased risk of future strokes or other cardiovascular events.[1] In ischaemic stroke survivors, statins and inhibitors of proprotein convertase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ae8f1f79bd1fcbeb82df55ef47bac693
https://doi.org/10.1093/eurheartj/ehab724.2026
https://doi.org/10.1093/eurheartj/ehab724.2026